RESUMEN
Amylomyces rouxii eliminated 85% of initial pentachlorophenol (PCP) at 12.5 mg l(-1) when grown with 0.1 g tyrosine l(-1), but only 55% without tyrosine. Addition of tyrosine in the culture medium increased the monophenolase activity by 1.8-fold. Tyrosinase is thus indicated to be the phenoloxidase involved in PCP degradation by A. rouxii .
Asunto(s)
Proteínas Fúngicas/química , Hongos/enzimología , Monofenol Monooxigenasa/química , Pentaclorofenol/química , Biodegradación AmbientalAsunto(s)
Linfoma de Células B Grandes Difuso/diagnóstico , Síndromes Paraneoplásicos Endocrinos/etiología , Prolactina/sangre , Neoplasias del Cuello Uterino/diagnóstico , Diagnóstico Diferencial , Femenino , Galactorrea/complicaciones , Humanos , Lactante , Linfoma de Células B Grandes Difuso/complicaciones , Neoplasias del Cuello Uterino/complicacionesRESUMEN
Cyclophosphamide was administered to 42 patients with acute lymphocytic leukemia (ALL) as a daily continuous iv infusion at a dose of 400 mg/m2/day x 5 days; the courses of treatment were repeated every 3 weeks. Of the 42 patients entered, 21 achieved a complete response, two achieved a partial response, 12 failed to respond, and seven were considered to have early deaths. The response rate was 69.5% if only patients who received adequate trials are considered; mean duration of response was 18.5 weeks and mean survival time was 24.2 weeks. Twenty-three patients had relapsed after previous chemotherapy, and 19 patients were untreated for advanced high-risk cases of ALL; no difference was found in the response rates, durations of response, and survival times between these groups. No significant genitourinary toxicity occurred. Myelosuppression became the dose-limiting toxic effect. Continuous infusion of cyclophosphamide is a clinically effective method of ALL treatment and may have a role in the initial combination regimens for this hematologic malignancy.
